The Supreme Court judgment on the Novartis-Glivec case has gone beyond technical and legal issues and linked the question of patenting with net benefits to society. What the judgment says and what it implies has significance for patent regimes in developing countries
The Supreme Court decision denying Novartis a patent for the cancer drug imanitib has been hailed as a victory for the affordable medicines movement. But it won’t make much difference if doctors continue to prescribe expensive branded drugs, patients believe that only expensive drugs work, and the government does little to support the manufacture of affordable medicines
The draft National Pharmaceuticals Pricing Policy 2011 brings 348 essential drugs under price control, but what about non-essential drugs, which are the bulk of those sold and which can be priced several times higher than their manufacturing cost, asks S Srinivasan
The new National Vaccine Policy Draft 2011openly favours industry. It provides for advance market commitments for new vaccines, whereby government guarantees a market for the vaccine before it is tested and even if it is not efficacious. Should our vaccine policy focus on the health of our children, or the viability of the vaccine industry?
As drug companies flock to India to conduct drug trials on the cheap, they capitalise on a combination of money-hungry researchers, a vulnerable population and a lax regulatory system. This is fertile ground for ethical violations that threaten the health and rights of poor Indians. Read Ankur Paliwal’s article in Down To Earth
India is a global exporter of vaccines but 50% of our children under one are not completely immunised. The government has ordered the reopening of vaccine-manufacturing PSUs, but a strategic plan on consistently meeting India's basic vaccine needs is still not clear. Venkat Srinivasan tells the story of India’s vaccine production programme, a story of politics, dishonesty and misguided priorities
The government’s move to scale up and subsidise community health insurance schemes while doing nothing to improve healthcare service delivery is a flawed strategy. It’s like getting PDS shops to distribute mango kernels and mahua seeds as drought relief instead of foodgrains since the poor survive on these anyway, says Oommen C Kurian
In a country where 26% of participants are enrolling for clinical trials just so that they get free or quality healthcare, it is dangerous to allow contract research organisations easy access to patient databases and to offer medicos payment for recruiting patients in trials, says Sandhya Srinivasan